Patents by Inventor Yen-Ta Lu
Yen-Ta Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240084017Abstract: Monoclonal antibodies against human Mac-1 are provided. These antibodies can bind to different states of Mac-1 so as to alter the biofunctions of Mac-1. These antibodies can modulate Th1/Th2 cytokine secretions by TLR-activated immune cells and can be used for the treatments of diseases related to acute and chronic inflammatory disorders, such as infectious diseases, and cancers.Type: ApplicationFiled: December 30, 2021Publication date: March 14, 2024Applicant: Ascendo Biotechnology, Inc.Inventors: Yen-Ta Lu, Chia-Ming Chang, Ping-Yen Huang, I-Fang Tsai, Frank Wen-Chi Lee
-
Publication number: 20240002515Abstract: Provided are an anti-CD11b antibody or an antigen-binding portion thereof, and methods and use of the antibody for modulating immunoresponses by regulating CD11b expression on cells.Type: ApplicationFiled: May 18, 2023Publication date: January 4, 2024Applicant: Ascendo Biotechnology, Inc.Inventors: Yen-Ta Lu, Chia-Ming Chang, Tsai-Yin Wei, I-Fang Tsai, Ling-Chiao Wu
-
Publication number: 20230330222Abstract: A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.Type: ApplicationFiled: May 14, 2021Publication date: October 19, 2023Applicant: Ascendo Biotechnology, Inc.Inventors: Yen-Ta Lu, Chia-Ming Chang, Ping-Yen Huang, I-Fang Tsai, Frank Wen-Chi Lee
-
Patent number: 11685785Abstract: A method for reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a composition to a subject in need of such treatments, wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.Type: GrantFiled: June 12, 2016Date of Patent: June 27, 2023Assignee: Ascendo Biotechnology, Inc.Inventors: Yen-Ta Lu, Chia-Ming Chang, Tsai-Yin Wei, I-Fang Tsai, Ling-Chiao Wu
-
Patent number: 11254069Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: GrantFiled: May 24, 2021Date of Patent: February 22, 2022Assignees: Topkey Corporation, Xiamen Keentech Composite Technology Co., Ltd.Inventors: Chih-Ming Chuang, Wan-Ting Chung, Yen-Ta Lu
-
Patent number: 11247412Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: GrantFiled: May 24, 2021Date of Patent: February 15, 2022Assignees: Topkey Corporation, Xiamen Keentech Composite Technology Co., Ltd.Inventors: Chih-Ming Chuang, Wan-Ting Chung, Yen-Ta Lu
-
Publication number: 20210324084Abstract: A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.Type: ApplicationFiled: August 9, 2019Publication date: October 21, 2021Applicant: Ascendo Biotechnology, Inc.Inventors: Yen-Ta LU, Ping-Yen HUANG, Chia-Ming CHANG, I-Fang TSAI, Frank Wen-Chi LEE, Huei-Ling CHANG
-
Publication number: 20210276277Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: ApplicationFiled: May 24, 2021Publication date: September 9, 2021Applicants: TOPKEY CORPORATION, XIAMEN KEENTECH COMPOSITE TECHNOLOGY CO., LTD.Inventors: Chih-Ming CHUANG, Wan-Ting CHUNG, Yen-Ta LU
-
Publication number: 20210276278Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: ApplicationFiled: May 24, 2021Publication date: September 9, 2021Applicants: TOPKEY CORPORATION, XIAMEN KEENTECH COMPOSITE TECHNOLOGY CO., LTD.Inventors: Chih-Ming CHUANG, Wan-Ting CHUNG, Yen-Ta LU
-
Patent number: 11046022Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: GrantFiled: September 20, 2018Date of Patent: June 29, 2021Assignees: Topkey Corporation, Xiamen Keentech Composite Technology Co., Ltd.Inventors: Chih-Ming Chuang, Wan-Ting Chung, Yen-Ta Lu
-
Publication number: 20200339557Abstract: The present invention relates to benzoxazole derivatives having the following Formula (I): The compounds of the present invention are found to possess the ability to decrease PD-L1 level, suggesting that the compounds of the invention can be used in cancer immunotherapy and treatment or prevention of sepsis or septic shock.Type: ApplicationFiled: July 9, 2020Publication date: October 29, 2020Applicant: MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITALInventors: Yen-Ta LU, Tzenge-Lien SHIH, Chia-Ming CHANG, Tsai-Yin WEI, Jen-Wei LIU
-
Publication number: 20200255531Abstract: The present invention relates to methods for modulating immune response based on binding I-domain of CD11b on the tumor associated myeloid cells (TAMCs) in the tumor microenvironment. Particularly, binding to I-domain of CD11b with anti-CD11b-I-domain antibody triggers immunostimulatory environment that have one or more of the following effects in the tumor microenvironment: increase the inflammatory cytokine in the tumor microenvironment, decrease the population of IDO+ myeloid suppresser cells, up-regulate M1 marker over M2 marker on the tumor associated macrophage, increase M1:M2 tumor associated macrophage ratio, promote differentiation of dendritic cells (DC), nature killer dendritic cells (NKDC), and plasmacytoid dendritic cells (pDC), increase population of 4?1BB+PD?1+ neoantigen specific CD8 T cells. Converting cold (non-inflamed) to hot (inflamed) tumor by binding to I-domain of CD11b with anti-CD11b-I-domain antibody allows enhanced effectiveness of immune response modulator.Type: ApplicationFiled: November 5, 2018Publication date: August 13, 2020Applicants: MACKAY MEMORIAL HOSPITAL, ASCENDO BIOTECHNOLOGY, INC.Inventors: Yen-Ta Lu, Chia-Ming Chang, I-Fang Tsai, Meng-Ping Lu, Haishan Jang, Ping-Yen Huang
-
Publication number: 20190091943Abstract: A composite material body (10) includes a first material layer (20) and a second material layer (30) overlapping the first material layer (20). The first material layer (20) and the second material layer (30) are wound to form a flexible and circular rod. Impact absorption is effectively improved and impact resisting strength is enhanced because energy-absorber or damping material or its composition is attached into the composite material body (10). Technical characteristics, effects and objects of this invention are achieved thereby.Type: ApplicationFiled: September 20, 2018Publication date: March 28, 2019Inventors: Chih-Ming CHUANG, Wan-Ting CHUNG, Yen-Ta LU
-
Publication number: 20180362651Abstract: A method fits reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a co position to a subject in need of such treatments wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.Type: ApplicationFiled: June 12, 2016Publication date: December 20, 2018Applicant: Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial HospitalInventors: Yen-Ta LU, Chia-Ming CHANG, Tsai-Yin WEI, I-Fang TSAI, Ling-Chiao WU
-
Publication number: 20180141991Abstract: A method for modulating an immunoresponse includes binding a TREM-like transcript 1 (TLT-1) polypeptide to an immune cell, wherein the binding of the TLT-1 polypeptide to the immune cell suppresses immunoresponse. A method for treating and/or preventing a disease associated with immune hyper-reactivity includes administering the TLT-1 polypeptide to a subject in need thereof.Type: ApplicationFiled: June 12, 2016Publication date: May 24, 2018Applicant: Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial HospitalInventors: Yen-Ta LU, Chia-Ming CHANG, Tsai-Yin WEI
-
Publication number: 20170283408Abstract: The present invention relates to benzoxazole derivatives having the following Formula (I): The compounds of the present invention are found to possess the ability to decrease PD-L1 level, suggesting that the compounds of the invention can be used in cancer immunotherapy and treatment or prevention of sepsis or septic shock.Type: ApplicationFiled: September 17, 2015Publication date: October 5, 2017Inventors: YEN-TA LU, TZENGE-LIEN SHIH, CHIA-MING CHANG, TSAI-YIN WEI, JEN-WEI LIU
-
Patent number: 9454566Abstract: A device for data management, the device is in communication with a memory and includes: a verification module configured to receive a first identity information and a first request and verify the first identity information; a search module configured to search for at least one first data stored in the memory in response to the first request if the first identity information is verified, the at least one first data being assigned a first rating point; and an evaluation module configured to receive a second rating point associated with the first identification information, retrieve the first rating point from the at least one first data and generate a third rating point in accordance with the verified first identity information, the first rating point and the second rating point and store the third rating point in the memory.Type: GrantFiled: July 11, 2013Date of Patent: September 27, 2016Assignee: Mackay Memorial HospitalInventors: Chi-Kuan Chen, Yen-Ta Lu, Wan-Ting Chen
-
Publication number: 20140019469Abstract: A device for data management, the device is in communication with a memory and includes: a verification module configured to receive a first identity information and a first request and verify the first identity information; a search module configured to search for at least one first data stored in the memory in response to the first request if the first identity information is verified, the at least one first data being assigned a first rating point; and an evaluation module configured to receive a second rating point associated with the first identification information, retrieve the first rating point from the at least one first data and generate a third rating point in accordance with the verified first identity information, the first rating point and the second rating point and store the third rating point in the memory.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Applicant: Mackay Memorial HospitalInventors: Chi-Kuan Chen, Yen-Ta Lu, Wan-Ting Chen
-
Patent number: 8491894Abstract: The present invention discloses a method for inhibiting the growth of Mycobacterium tuberculosis, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of Mycobacterium tuberculosis. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry of Mycobacterium tuberculosis into monocytes, reduce survival of Mycobacterium tuberculosis in monocytes, and kill Mycobacterium tuberculosis effectively.Type: GrantFiled: June 20, 2011Date of Patent: July 23, 2013Assignee: Mackay Memorial HospitalInventors: Yen-Ta Lu, I-Fang Tsai
-
Patent number: 8455474Abstract: Disclosed is a method for treating a symptom of M. tuberculosis infection in a subject, comprising administering the patient with an effective amount of (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)zetidin-2-one (EZETIMIBE). In the preferred embodiments, EZETIMIBE is capable of significantly inhibiting the survival and proliferation of Mycobacterium tuberculosis in the monocytes. The anti-tuberculous effect of EZETIMIBE is partly through stimulating CD13 leading to monocytes activation and thus bacterial killing of Mycobacterium tuberculosis, and partly through depleting the intracellular nutrition necessary for the survival of Mycobacterium tuberculosis. It is also proved that EZETIMIBE is capable of directly killing Mycobacterium tuberculosis outside cells.Type: GrantFiled: March 4, 2011Date of Patent: June 4, 2013Assignee: Mackay Memorial HospitalInventors: Yen-Ta Lu, I-Fang Tsai